References

  1. Criton S, Devi K, Sridevi PK, Asokan PU. Toxic epidermal necrolysis-a retrospective study. Int J Dermatol. 1997; 36(12): 923-5. PubMed | Google Scholar

  2. Wolkenstein P, Revuz J. Drug-induced severe skin reactions: incidence, management and prevention. Drug Saf. 1995; 13(1): 56-68. PubMed | Google Scholar

  3. Rzany B, Correia O, Kelly JP, Naldi L, Auquier A, Stern R. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study; Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. Lancet. 1999; 353(9171): 2190-4. PubMed | Google Scholar

  4. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129(1):92-6. PubMed | Google Scholar

  5. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-45. PubMed | Google Scholar

  6. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000; 115(2): 149-53. PubMed | Google Scholar

  7. Fritsch PO, Sidoroff A. Drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Am J Clin Dermatol. 2000; 1(6): 349-60. PubMed | Google Scholar

  8. Schopf E, Stuhmer A, Rzany B, Victor N, Zentgraf R, Kapp JF. Toxic epidermal necrolysis and Stevens-Johnson syndrome: an epidemiologic study from West Germany. Arch Dermatol. 1991; 127(6): 839-42. PubMed | Google Scholar

  9. Wong KC, Kennedy PJ, Lee S. Clinical manifestations and outcomes in 17 cases of Stevens-Johnson syndrome and toxic epidermal necrolysis. Australas J Dermatol. 1999;40(3):131-4. PubMed | Google Scholar

  10. Naveen KN, Pai VV, Rai V, Athanikar SB. Retrospective analysis of Steven Johnson syndrome and toxic epidermal necrolysis over a period of 5 years from northern Karnataka, India. Indian J Pharmacol. 2013; 45(1): 80-2. PubMed | Google Scholar

  11. Devi K, George S, Criton S, Suja V, Sridevi PK. Carbamazepine--the commonest cause of toxic epidermal necrolysis and Stevens-Johnson syndrome: a study of 7 years. Indian J Dermatol Venereol Leprol. 2005; 71(5): 325-8. PubMed | Google Scholar

  12. Halevy S, Ghislain PD, Mockenhaupt M, et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol. 2008; 58(1): 25-32. PubMed | Google Scholar

  13. Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs: the EuroSCAR-study. J Invest Dermatol. 2008; 128(1): 35-44. PubMed | Google Scholar

  14. Palmieri TL, Greenhalgh DG, Saffle JR, et al. A multicenter review of toxic epidermal necrolysis treated in US burn centers at the end of the twentieth century. J Burn Care Rehabil. 2002; 23(2): 87-96. PubMed | Google Scholar